-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Padeliporfin Potassium in Esophageal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Padeliporfin Potassium in Esophageal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Padeliporfin Potassium in Esophageal Cancer Drug Details: Padeliporfin dipotassium (Tookad) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Hexaminolevulinate Hydrochloride in Cervical Intraepithelial Neoplasia (CIN) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Gamma-PN in Streptococcal Pneumonia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Gamma-PN in Streptococcal Pneumonia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Gamma-PN in Streptococcal Pneumonia Drug Details: Gamma-PN vaccine is under development for the...
-
Company Profile
Pear Therapeutics Inc – Company Profile
Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. The company’s lead product candidate is reSET for treating substance use disorder. Its product pipeline includes reSET-O for the treatment of opioid use disorder (OUD) in conjunction with opioid replacement therapy; Somryst against chronic insomnia; PEAR-004 targeting schizophrenia; and PEAR-006 for treating multiple sclerosis. The company’s PDT platform is developing therapies targeting Alzheimer's disease, autoimmune disorders, depression, gastrointestinal disorders, migraine, and...
Add to Basket -
Product Insights
NewPear Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Pear Therapeutics Inc Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. The company’s lead product candidate is reSET for treating substance use disorder. Its product pipeline includes reSET-O for the treatment of opioid use disorder (OUD) in conjunction with opioid replacement therapy; Somryst against chronic insomnia; PEAR-004 targeting schizophrenia; and PEAR-006...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – hexaminolevulinate hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry hexaminolevulinate hydrochloride Drug Details Cevira (APL-1702) is under development for the treatment of cervical...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – aminolevulinic acid hydrochloride
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry aminolevulinic acid hydrochloride Drug Details Aminolevulinic acid hydrochloride (Ameluz) is a dermatological agent. It...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – padeliporfin potassium
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry padeliporfin potassium Drug Details Padeliporfin dipotassium (Tookad) is a vascular-acting photosensitizer consisting of a...
-
Product Insights
Basal Cell Carcinoma (Basal Cell Epithelioma) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. The basal cell carcinoma pipeline drugs market research report provides an analysis of the basal cell carcinoma drugs by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The guide also covers...